Anna Gueiderikh

Dr. Anna Gueiderikh


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
AGAnna Gueiderikh
Anna Gueiderikh
FMFrédérique Maczkowiak-Chartois
Frédérique Maczkowiak-Chartois
GRGuillaume Rouvet
Guillaume Rouvet
SSSylvie Souquère-Besse
Sylvie Souquère-Besse
SASébastien Apcher
Sébastien Apcher
FRFilippo Rosselli
Filippo Rosselli
FANCA is a multitasking protein with essential functions beyond DNA repair in nucleolar homeostasis and ribosome biogenesis.

1 March 2022 in Blood Reviews
Verified
Journal Article
Open access
AGAnna Gueiderikh
Anna Gueiderikh
FMFrédérique Maczkowiak-Chartois
Frédérique Maczkowiak-Chartois
FRFilippo Rosselli
Filippo Rosselli
Described by Guido Fanconi almost 100 years ago, Fanconi anemia (FA) is a rare genetic disease characterized by developmental abnormalities, bone marrow failure (BMF) and cancer predisposition. The proteins encoded by FA-mutated genes (FANC proteins) and assembled in the so-called FANC/BRCA pathway have key functions in DNA repair and replication safeguarding, which loss leads to chromosome structural aberrancies. Therefore, since the 1980s, FA has been considered a genomic instability and chromosome fragility syndrome. However, recent findings have demonstrated new and unexpected roles of FANC proteins in nucleolar homeostasis and ribosome biogenesis, the alteration of which impacts cellular proteostasis. Here, we review the different cellular, biochemical and molecular anomalies associated with the loss of function of FANC proteins and discuss how these anomalies contribute to BMF by comparing FA to other major inherited BMF syndromes. Our aim is to determine the extent to which alterations in the DNA damage response in FA contribute to BMF compared to the consequences of the loss of function of the FANC/BRCA pathway on the other roles of the pathway.

10 September 2025 in Cancer/Radiothérapie
Verified
Journal Article
Open access
AGAnna Gueiderikh
Anna Gueiderikh
MMMorgan Michalet
Morgan Michalet
CDCatherine Dejean
Catherine Dejean
USUlrike Schick
Ulrike Schick
CDCatherine Durdux
Catherine Durdux
YKYoulia Kirova
Youlia Kirova
We present the updated recommendations of the Société française de radiothérapie oncologique (SFRO, the French society for radiation oncology) on radiotherapy and pregnancy. The occurrence of cancer during pregnancy is a rare event (approximately 1 in 1000 pregnancies). The risks for the embryo or the foetus depend on the gestational age at the time of irradiation. The main risks are malformations with microcephaly and mental retardation. There is also a risk of radiation-induced cancer in the unborn child. In the case of only supradiaphragmatic irradiation, radiotherapy can be performed most often in pregnant women without risk to the foetus. On the other hand, in the case of an indication for subdiaphragmatic irradiation, therapeutic termination of the pregnancy should be proposed. In all cases, when radiotherapy is chosen, a phantom estimation of the dose delivered to the foetus, confirmed by in vivo measurement, is recommended. Conformational radiotherapy is the preferred technique because of the lower dose delivered to the foetus (except for tumour locations where other techniques such as intensity-modulated radiotherapy are recommended).

6 May 2023 in Cancer/Radiothérapie
Verified
Journal Article
Closed access
AGAnna Gueiderikh
Anna Gueiderikh
MUM. Ung
M. Ung
JLJ. Lazarovici
J. Lazarovici
ADA. Danu
A. Danu
DGD. Ghez
D. Ghez
VMV. Martin
V. Martin

14 November 2025 in Cancer and Metastasis Reviews
Verified
Journal Article
Closed access
PDF file
CGConstance Golfier
Constance Golfier
AVAude Visy
Aude Visy
AGAnna Gueiderikh
Anna Gueiderikh
JMJohann MARCEL
Johann MARCEL
AEAlexandre Escande
Alexandre Escande
JFJean-Christophe Faivre
Jean-Christophe Faivre

16 May 2026 in Clinical and Translational Radiation Oncology
Verified
Journal Article
Open access
AGAnna Gueiderikh
Anna Gueiderikh
APAdrien Panis
Adrien Panis
SKSylvain Klotz
Sylvain Klotz
DMDamien Moreau
Damien Moreau
YMYannis Meraouna
Yannis Meraouna
PGPhilippe Giraud
Philippe Giraud
Kidney transplant candidates increasingly present with localized or locally advanced prostate cancer. While radiotherapy is frequently indicated, current planning guidelines do not account for the surgical constraints of future kidney transplantation. This study proposes a practical planning framework by defining transplant-specific organs at risk (OARs) and evaluating the dosimetric impact of their systematic optimization during prostate cancer radiotherapy. Through multidisciplinary collaboration between radiation oncologists and transplant surgeons, transplantation-critical structures were identified and delineated, including the bladder dome, ureters, and peri-vascular iliac fat. A comparative dosimetric analysis was performed across six planning strategies applied to two representative anatomical situations reflecting different bladder volumes: prostate-only Intensity Modulated Radiation Therapy (IMRT) with and without transplant-specific OARs optimization, stereotactic body radiotherapy (SBRT), and prostate plus pelvic nodal IMRT with and without optimization. Dose metrics to transplant-specific and conventional OARs were analyzed. In prostate-only treatments, active optimization of transplant-specific OARs resulted in a threefold or greater reduction in mean dose to the bladder dome, without compromising target coverage or increasing doses to conventional OARs. Similar dose reductions were observed for ureters and peri-vascular iliac external fat. SBRT achieved the lowest absolute doses to all transplant-specific OARs. In contrast, when pelvic lymph nodes were included, optimization failed to meaningfully reduce doses, with mean values exceeding 20 Gy for several transplant-critical structures. This work establishes a planning framework for integrating kidney transplantation constraints into prostate cancer radiotherapy. Prostate-only radiotherapy allows effective sparing of transplant-critical structures through active optimization, whereas pelvic nodal irradiation inevitably exposes these structures to high doses despite optimization. These findings support transplant-oriented treatment planning and careful selection of pelvic irradiation in kidney transplant candidates.